Testicular cancer is highly curable, but it is also uncommon, and consequently, there is a tendency for less experienced clinicians to over-treat, leading to long-term consequences that young men will experience for the rest of their lives.
Helping young men live better is now the focus of testicular cancer research, with novel treatment options and personalised medicine through improved biomarkers. Professor Ben Tran describes the advances we continue to make, 50 years after cisplatin first cured testicular cancer.
Dr Liow is a medical oncologist at Monash Health focusing on genitourinary cancers including testicular cancer. She is undertaking a PhD at WEHI studying real-world kidney cancer outcomes using multi-site registry data, including work linked to the International Metastatic RCC Database Consortium (IMDC).
Prof Tran leads the GU medical oncology team at Peter Mac and is recognised as a global leader in testicular cancer. His research interests include Early Drug Development, with a focus on novel IO approaches in GU cancers. He also has an interest in Real World Evidence generation/analysis, leading multi-site, multi-national clinical registries in GU cancers. Prof Tran also Chairs the Phase 1 group within Cancer Trials Australia, and the Testicular Germ Cell Tumour subcommittee within the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.
